Skye Bioscience, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before January 16, 2026 to Discuss Your Rights – SKYE

Core Viewpoint - A class action securities lawsuit has been filed against Skye Bioscience, Inc. due to alleged securities fraud affecting investors between November 4, 2024, and October 3, 2025 [1][2]. Group 1: Lawsuit Details - The complaint alleges that the company's lead product candidate, nimacimab, was less effective than previously claimed, leading to overstated clinical, regulatory, and commercial prospects [2]. - Defendants' public statements regarding nimacimab were materially false and misleading throughout the relevant period [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].